Back to Search
Start Over
Cancer de l’ovaire : la rechute précoce
- Source :
- Bulletin du Cancer, Bulletin du Cancer, John Libbey Eurotext, 2017, Updated 2016 recommendations for the clinical practice of Nice/Saint-Paul-de-Vence in ovarian cancer and advanced cervical cancer, 104, pp.S32-S38. 〈10.1016/S0007-4551(17)30160-1〉, Bulletin du Cancer, John Libbey Eurotext, 2017, Updated 2016 recommendations for the clinical practice of Nice/Saint-Paul-de-Vence in ovarian cancer and advanced cervical cancer, 104, pp.S32-S38. ⟨10.1016/S0007-4551(17)30160-1⟩, Bulletin du Cancer, 2017, Updated 2016 recommendations for the clinical practice of Nice/Saint-Paul-de-Vence in ovarian cancer and advanced cervical cancer, 104, pp.S32-S38. ⟨10.1016/S0007-4551(17)30160-1⟩
- Publication Year :
- 2017
- Publisher :
- HAL CCSD, 2017.
-
Abstract
- National audience; La rechute précoce est définie par une récidive qui survient moins de 6 mois après la dernière injection de chimiothérapie à base de platine. Elle peut être primaire ou secondaire, et après une ou plusieurs lignes de traitements avec un sel de platine. Il n’y a pas d’indication à une chirurgie carcinologique. Il est recommandé une monochimiothérapie sans platine (doxorubicine liposomale pégylée [DLP], paclitaxel hebdomadaire, topotécan ou gemcitabine) en association avec du bévacizumab si la patiente n’en a pas reçu antérieurement (niveau de preuve 1, grade A). Early relapse (primary or secondary) is defined by relapse of disease less than 6 months before the last infusion of chemotherapy (with a platinum compound). There is no carcinological surgical indication. Disease should be treated with a non-platinum single agent (pegylated liposomal doxorubicin, weekly paclitaxel, gemcitabine or topotecan). Bevacizumab can be added if patients have not already received it (level of proof 1, grade A).
- Subjects :
- 0301 basic medicine
Cancer Research
Cancer de l’ovaire
[SDV.CAN]Life Sciences [q-bio]/Cancer
Hematology
General Medicine
[ CHIM ] Chemical Sciences
3. Good health
[ SDV.CAN ] Life Sciences [q-bio]/Cancer
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
ovarian cancer
Oncology
030220 oncology & carcinogenesis
[CHIM]Chemical Sciences
Radiology, Nuclear Medicine and imaging
Early relapse
Rechute précoce
Subjects
Details
- Language :
- French
- ISSN :
- 00074551 and 17696917
- Database :
- OpenAIRE
- Journal :
- Bulletin du Cancer, Bulletin du Cancer, John Libbey Eurotext, 2017, Updated 2016 recommendations for the clinical practice of Nice/Saint-Paul-de-Vence in ovarian cancer and advanced cervical cancer, 104, pp.S32-S38. 〈10.1016/S0007-4551(17)30160-1〉, Bulletin du Cancer, John Libbey Eurotext, 2017, Updated 2016 recommendations for the clinical practice of Nice/Saint-Paul-de-Vence in ovarian cancer and advanced cervical cancer, 104, pp.S32-S38. ⟨10.1016/S0007-4551(17)30160-1⟩, Bulletin du Cancer, 2017, Updated 2016 recommendations for the clinical practice of Nice/Saint-Paul-de-Vence in ovarian cancer and advanced cervical cancer, 104, pp.S32-S38. ⟨10.1016/S0007-4551(17)30160-1⟩
- Accession number :
- edsair.doi.dedup.....68888cf546682767b7d72ae733af497d